FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334296428> ?p ?o ?g. }

• W2334296428 endingPage "A66" @default.
• W2334296428 startingPage "A65.3" @default.
• W2334296428 abstract "<h3>Introduction</h3> The impact of stopping anti-TNF for patients in clinical and/or endoscopic remission in routine clinical practise setting is uncertain. We aimed to evaluate clinical outcomes in patients who discontinued anti-TNF electively across 3 units in the Yorkshire & Humber IBD Network, UK. <h3>Methods</h3> Crohn’s disease (CD) patients in whom anti-TNF (62 infliximab (IFX), 9 adalimumab (ADA)) was stopped electively following a planned assessment were included. All had been treated for ≥ 12 months and followed-up for ≥ 3 months following cessation of anti-TNF. Investigations at assessment prior to cessation included ≥ 1 of; colonoscopy, colon capsule (CC), small bowel capsule (SBC), magnetic resonance enterography (MRE), barium study (BS), CRP and clinical assessment (CA). <h3>Results</h3> Seventy-one patients (44 female; median age at diagnosis 24 years) were included with a median duration of IBD prior to anti-TNF of 24 (0–264) months. Indications were severe active luminal (50/71), fistulating perianal (18/71) and other fistulating disease (3/71). The median treatment duration was 18 months (range 12–78) with 62 (87%) on immunomodulators post anti-TNF withdrawal. Relapse rates within 90,180 and 365 days were 3/71(4.2%), 14/67(21%) and 27/57(47%) respectively. In perianal disease alone, the relapse rate was 6/18 (33%) at 1 year. 25 of those who relapsed were retreated with anti-TNF, with an overall recapture rate of 84%. In those retreated with the same agent as previously withdrawn the response rate was 80%. A further 5 were successfully retreated with ADA when IFX had been withdrawn. Those (6) who had a dose escalation in 6 months prior to withdrawal all relapsed. Assessment practise changed following NICE guidance in 2010. Prior to this 5/15(33%) stopping anti-TNF had a CA alone. Following NICE guidance 2/56 (3.6%) were assessed only by CA. Investigations to complement routine CA by Harvey Bradshaw Index (HBI), included ≥ 1 of colonoscopy (52), CC (4), MRE (19), SBC (5), BS (2) and CRP (66). HBI ≥ 4 and a CRP of ≥ 5 in the 6 months prior to formal assessment was observed in 26 patients. 14/26 (54%) relapsed following cessation of anti-TNF (positive predictive value of 61%). Further invasive investigations in this group were abnormal in 2 patients. <h3>Conclusion</h3> In this UK cohort, elective withdrawal of anti-TNF was associated with a relapse rate of 48% after 12 months, with a high retreatment response rate. Due to NICE guidance, increased invasive assessment occurred, but the role of endoscopy and imaging to evaluate remission prior to withdrawal of anti-TNF needs further evaluation. <h3>Disclosure of Interest</h3> A. Brooks: None Declared, S. Sebastian Conflict with: Dr Sebastian has participated in advisory boards and received speakers honoraria, educational and research grants from Abbott and MSD, K. Robinson: None Declared, L. Warren: None Declared, A. Wright: None Declared, A. Marsh: None Declared, H. Tsai Conflict with: Dr Tsai has participated in advisory boards and received speakers honoraria, educational and research grants from Abbott and MSD, F. Majeed: None Declared, M. McAlindon: None Declared, P. Hamlin Conflict with: Dr Hamlin has participated in advisory boards and received support for specialist nurses from Abbott and MSD, A. Lobo:None Declared" @default.
• W2334296428 created "2016-06-24" @default.
• W2334296428 creator A5003287352 @default.
• W2334296428 creator A5005550686 @default.
• W2334296428 creator A5031845389 @default.
• W2334296428 creator A5036522201 @default.
• W2334296428 creator A5039449952 @default.
• W2334296428 creator A5046490863 @default.
• W2334296428 creator A5050898131 @default.
• W2334296428 creator A5051362122 @default.
• W2334296428 creator A5058473011 @default.
• W2334296428 creator A5067628638 @default.
• W2334296428 creator A5068737747 @default.
• W2334296428 date "2013-06-01" @default.
• W2334296428 modified "2023-09-27" @default.
• W2334296428 title "PTU-054 Outcomes following Investigation and Elective Withdrawal of Anti-TNF Therapy in Crohn’S Disease: a UK Multicentre Study" @default.
• W2334296428 doi "https://doi.org/10.1136/gutjnl-2013-304907.146" @default.
• W2334296428 hasPublicationYear "2013" @default.
• W2334296428 type Work @default.
• W2334296428 sameAs 2334296428 @default.
• W2334296428 citedByCount "0" @default.
• W2334296428 crossrefType "journal-article" @default.
• W2334296428 hasAuthorship W2334296428A5003287352 @default.
• W2334296428 hasAuthorship W2334296428A5005550686 @default.
• W2334296428 hasAuthorship W2334296428A5031845389 @default.
• W2334296428 hasAuthorship W2334296428A5036522201 @default.
• W2334296428 hasAuthorship W2334296428A5039449952 @default.
• W2334296428 hasAuthorship W2334296428A5046490863 @default.
• W2334296428 hasAuthorship W2334296428A5050898131 @default.
• W2334296428 hasAuthorship W2334296428A5051362122 @default.
• W2334296428 hasAuthorship W2334296428A5058473011 @default.
• W2334296428 hasAuthorship W2334296428A5067628638 @default.
• W2334296428 hasAuthorship W2334296428A5068737747 @default.
• W2334296428 hasBestOaLocation W23342964281 @default.
• W2334296428 hasConcept C121608353 @default.
• W2334296428 hasConcept C126322002 @default.
• W2334296428 hasConcept C141071460 @default.
• W2334296428 hasConcept C2777138892 @default.
• W2334296428 hasConcept C2778260677 @default.
• W2334296428 hasConcept C2778435480 @default.
• W2334296428 hasConcept C2779134260 @default.
• W2334296428 hasConcept C2779280984 @default.
• W2334296428 hasConcept C2780132546 @default.
• W2334296428 hasConcept C526805850 @default.
• W2334296428 hasConcept C71924100 @default.
• W2334296428 hasConcept C90924648 @default.
• W2334296428 hasConceptScore W2334296428C121608353 @default.
• W2334296428 hasConceptScore W2334296428C126322002 @default.
• W2334296428 hasConceptScore W2334296428C141071460 @default.
• W2334296428 hasConceptScore W2334296428C2777138892 @default.
• W2334296428 hasConceptScore W2334296428C2778260677 @default.
• W2334296428 hasConceptScore W2334296428C2778435480 @default.
• W2334296428 hasConceptScore W2334296428C2779134260 @default.
• W2334296428 hasConceptScore W2334296428C2779280984 @default.
• W2334296428 hasConceptScore W2334296428C2780132546 @default.
• W2334296428 hasConceptScore W2334296428C526805850 @default.
• W2334296428 hasConceptScore W2334296428C71924100 @default.
• W2334296428 hasConceptScore W2334296428C90924648 @default.
• W2334296428 hasIssue "Suppl 1" @default.
• W2334296428 hasLocation W23342964281 @default.
• W2334296428 hasOpenAccess W2334296428 @default.
• W2334296428 hasPrimaryLocation W23342964281 @default.
• W2334296428 hasRelatedWork W2006318665 @default.
• W2334296428 hasRelatedWork W2034536484 @default.
• W2334296428 hasRelatedWork W2034892783 @default.
• W2334296428 hasRelatedWork W2131408481 @default.
• W2334296428 hasRelatedWork W2165978718 @default.
• W2334296428 hasRelatedWork W2297514571 @default.
• W2334296428 hasRelatedWork W2617260208 @default.
• W2334296428 hasRelatedWork W3022383156 @default.
• W2334296428 hasRelatedWork W3092204953 @default.
• W2334296428 hasRelatedWork W3184875481 @default.
• W2334296428 hasVolume "62" @default.
• W2334296428 isParatext "false" @default.
• W2334296428 isRetracted "false" @default.
• W2334296428 magId "2334296428" @default.
• W2334296428 workType "article" @default.